ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...

The Company's first-class scientific team continues to make good progress with CBR and, once sufficient resources are provided, the Company anticipates moving new CBR-based product candidates into ...

To improve the efficacy of gene therapy when using anti-sickling beta globin gene transfer, they added cyclosporin (CsH) to increase transduction by inhibiting lentiviral restriction factors.

Lentiviral transduction of producer cells, followed by expansion of transduced cells, amplified the fraction of producer cells with a single barcode-capsid variant pair. The barcoded eVLP capsid ...

On the basis of product type, the viral vectors segment is expected to hold a dominant position. This is owing to its high transduction efficiency. On the basis of grade, GMP grade plasmid DNA segment ...